Review

Rice Compounds with Impact on Diabetes Control

Cristiana Pereira ¹, Vanda M. Lourenço ², Regina Menezes ³,⁴,⁵ and Carla Brites ¹,⁶,*

¹ National Institute for Agricultural and Veterinary Research (INIAV), I.P., Av. da República, 2780-157 Oeiras, Portugal; cristianapereirags@gmail.com
² Faculty of Sciences and Technology (FCT) & Center for Mathematics and Applications (CMA), NOVA University of Lisbon, 2829-516 Caparica, Portugal; vmml@fct.unl.pt
³ CBIOS—Universidade Lusófona’s Research Center for Biosciences & Health Technologies, Campo Grande 376, 1749-024 Lisboa, Portugal; regina.menezes@ulusofona.pt
⁴ CEDOC, Chronic Diseases Research Centre, NOVA Medical School / Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, 1169-056 Lisboa, Portugal
⁵ iBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2781-901 Oeiras, Portugal
⁶ GREEN-IT Bioresources for Sustainability, ITQB NOVA, Av. da República, 2780-157 Oeiras, Portugal
* Correspondence: carla.brites@iniav.pt

Abstract: Rice is one of the most cultivated and consumed cereals worldwide. It is composed of starch, which is an important source of diet energy, hypoallergenic proteins, and other bioactive compounds with known nutritional functionalities. Noteworthy is that the rice bran (outer layer of rice grains), a side-stream product of the rice milling process, has a higher content of bioactive compounds than white rice (polished rice grains). Bran functional ingredients such as γ-oryzanol, phytic acid, ferulic acid, γ-aminobutyric acid, tocopherols, and tocotrienols (vitamin E) have been linked to several health benefits. In this study, we reviewed the effects of rice glycemic index, macronutrients, and bioactive compounds on the pathological mechanisms associated with diabetes, identifying the rice compounds potentially exerting protective activities towards disease control. The effects of starch, proteins, and bran bioactive compounds for diabetic control were reviewed and provide important insights about the nutritional quality of rice-based foods.

Keywords: diabetes; rice bran; phytic acid; vitamin E; γ-oryzanol; γ-aminobutyric acid; ferulic acid; GLUT1; SGLT2; IAPP

1. Introduction

Diabetes Mellitus (DM) is a spectrum of metabolic diseases affecting hundreds of millions of people worldwide, whose numbers are expected to continue increasing in the following years [1]. As a diet-related disease, DM prevention requires a strict diet along with therapeutic control [2]. The disease is characterized by increased blood glucose levels, which can arise from two main causes, leading to its classification as type 1 and type 2 Diabetes Mellitus (T1DM and T2DM, respectively) [3,4]. In T1DM, an autoimmune disease corresponding to ~5–10% of all diabetes cases, the immune system destroys the insulin-producing β-cells of the pancreas. In T2DM (hereafter referred to as diabetes), a condition that corresponds to ~90–95% of all diabetes cases [5], cells become resistant to insulin, leading to the dysregulation of glucose metabolism.

Rice, one of the staple foods of the world’s population, is consumed as white cooked polished grain and is a high glycemic index (GI) food (64–93%) [6]. Given its fundamental importance in the human diet, it is imperative to exhaustively evaluate rice nutritional composition, which can differ among varieties. Evaluation of the nutritional composition of white rice indicates that it is essentially composed of starch, with rice protein being the second largest nutrient in white rice (Table 1). These nutrients and other compounds present in the brown rice grain are relevant in the control of metabolic diseases, especially in diabetes control.
Table 1. Basic composition of white rice and rice bran (%) 1.

| Nutrients       | White Rice | Brown Rice | Rice Bran |
|-----------------|------------|------------|-----------|
| Carbohydrates   | 77.0–89.0  | 73.0–87.0  | 34.0–62.0 |
| Starch          | 77.6       | 66.4       | 13.8      |
| Lipids          | 0.3–0.5    | 1.6–2.8    | 15.0–19.7 |
| Protein         | 4.5–10.5   | 4.3–18.2   | 11.3–14.9 |
| Crude Fiber     | 0.2–0.5    | 0.6–1.0    | 7.0–11.4  |
| Dietary Fiber   | 0.7–2.7    | 2.9–4.4*   | 19.0–29.0*|
| Ash             | 0.3–0.8    | 1.0–1.5    | 6.6–9.9   |

1 Adapted from [7] and * [8]; Published by AACC International Press.

Brown rice has a higher content of nutritional compounds compared with white rice, except starch (Table 1). The health benefits of brown rice are mainly due to their proteins, lipids, vitamins, minerals, and dietary fiber contents [7,8]. Several in vivo studies have shown the benefits of brown rice-based or brown rice-supplemented diets in diabetes control, especially in reducing the glycemic index [9–11].

The rice milling industry generates large quantities of side-stream products without great valorization, such as rice bran [12], which represents about 10–13% of brown rice grain [13]. Notably, rice bran has greater lipids and dietary fibers than white rice (Table 1).

Rice bran contains less carbohydrates than white rice and twice as much protein (Table 1), and it is therefore an important protein source (such as rice albumin). Remarkably, rice bran is also rich in bioactive compounds such as γ-oryzanol, ferulic, phytic and γ-aminobutyric acids, tocopherols, and tocotrienols (vitamin E) (Table 2), which may differ in concentration depending on the variety and type of rice [14]. These compounds have been shown to exert hypolipidemic and anti-hypertensive effects, in addition to contributing to the mitigation of oxidative stress [14–17], a pathological process associated with diabetes [18,19]. Rice bran thus represents a great nutritional source of lipids, proteins, and non-starchy polysaccharides (accounted in the crude fiber fraction), richer than in white rice (Table 1), and can be used to produce new food ingredients such as rice bran oil or protein isolates.

Table 2. Main bioactive compounds in white rice and rice bran (mg/100 g).

| Compounds                     | White Rice | References | Rice Bran | References |
|-------------------------------|------------|------------|-----------|------------|
| γ-oryzanol                    | 5.0–7.2    | [20]       | 59.4–912.0| [21–24]    |
| Phytic acid                   | 13.0–1104.0| [25–27]    | 4000.0–22,500.0| [25,26,28,29]|
| Ferulic acid                  | 0.5–8.4    | [30,31]    | 1.4–225.4 | [31]       |
| γ-Aminobutyric acid           | 0.3–0.7    | [32]       | 10.7–58.0 (before grain germination) | [33–35] |
| Tocopherols and tocotrienols  | 0.6–1.8    | [20]       | 17.0–22.9 | [20,36,37] |
| (vitamin E)                   |            |            | 90.0–350.0 (after grain germination) |         |

The main purpose of this review is to describe the potential therapeutic effects of rice compounds in diabetes, especially the relevant macronutrients (starch, proteins; Section 2) via the control of the glycemic index and their effects in glycemia, and to discuss the value of rice bran compounds (Section 3). The effects of rice glycemic index, macronutrients, and bioactive compounds on the pathological mechanisms associated with diabetes are discussed to support the exploitation of rice compounds as functional ingredients in diabetes control (Section 4).
2. Rice Macronutrients

2.1. Starch

Starch is the main nutrient present in rice (77.6%) (Table 1) being, for this reason, the most influential ingredient in rice quality definition. It is also the main provider of the greatest amount of diet energy. Starch can be classified into three main categories based on its in vitro digestion: rapid digesting starch (RDS), slow digesting starch (SDS), and resistant starch (RS) [38]. Resistant starch is defined as starch, or products derived from starch digestion, that are not digested in the small intestine. It is important to address its effect on blood glucose as starches from different rice processed foods can have different digestion and absorption rates. Some studies have indicated that variability in the starch digestibility was associated with the great variability of the glycemic index (GI) in different types of rice [38,39], highlighting the importance of selecting new lower GI-varieties (Table 3) [40].

Table 3. Glycemic index (GI) values of different varieties of cooked rice according to ISO 26642:2010 1.

| Type of Rice                                      | GI   |
|--------------------------------------------------|------|
| Glutinous white rice (unique study)              | 98   |
| Glutinous white rice (unique study)              | 94   |
| Sticky rice, Thai glutinous rice (unique study)  | 92   |
| Jasmine white rice (mean of 18 studies)          | 89   |
| Japanese Style Sushi white rice (unique study)   | 85   |
| Arborio risotto rice (unique study)              | 69   |
| Carnaroli white rice (unique study)              | 64   |
| Parboiled rice (mean of 10 studies)              | 64   |
| Rice Long grain (mean of 6 studies)              | 62   |
| Basmati white rice boiled (mean of 10 studies)   | 60   |
| Taiken brown rice (japonica rice) (unique study) | 58   |
| Bapatla brown rice (indian rice) (unique study)  | 58   |

1 Adapted from [40]; Published by the American Society for Nutrition.

As such, the use of foods rich (or enriched) in RS is an asset and a potential strategy for reducing starch digestion rate [41–43] and blood glucose levels [38,44,45]. RS can be divided into five types: RS1 is a physically inaccessible starch, presented in compact food matrices, present essentially in whole grains; RS2 comes from starch that has not been gelatinized, appearing in non-gelatinized foods; RS3 exists in starch after retrogradation, showing better functional characteristics, namely low digestibility; RS4 is a modified starch prepared through enzymatic, chemical, physical, or genetic modifications, managing to be artificially increased; and RS5 is formed by an amylose-lipid complex [46,47]. Currently, there is a growing interest in RS4 for possible modification and improvement through physical, chemical, and enzymatic methods in order to obtain different types of RS with greater applicability [47,48]. Rice RS content can vary between 0.1–3.2% [49–52]. The properties of rice starch, such as size granules and crystallinity, amylose/amylopectin ratio, and gelatinization characteristics can also be predictors of starch digestion rate [38,39,51–53]. Extrinsic factors such as crop edaphoclimatic conditions largely influence basic starch composition, especially proteins and lipids, which may reduce the access of digestive enzymes to the starch hydrolysis [45,54,55]. These factors also influence the concentration of rice bioactive compounds [51,56,57], which will be discussed later.

Rice amylose content is the main starch feature that influences starch digestion. Its linear structure hampers amylolytic enzyme action. It is more resistant to digestion than amylopectin, with a branched structure. Therefore, high-amylose rice varieties were reported to have slower digestion starch than low-amylose varieties [39,58,59]. The positive
The correlation between amylose and RS concentrations in samples with a low GI is also reported [51,52]. In addition to chemical, physical, and enzymatic methods for modifying RS, genetic modification has also become important. Genetic manipulation acts essentially by starch manipulation, aiming to create highly resistant starch varieties. For this purpose, the genetic starch chain is modified through mutagenesis (with starch biosynthesis related genes) to accumulate a higher amylose content [47,60].

2.2. Proteins

White rice contains about 4.5–10.5% (Table 1) protein, being its second highest nutrient. Rice bran, with 11.3–14.9% total protein, contains twice the amount of protein than white rice. According to some authors, rice proteins play an important role in the starch digestion rate when interacting through their connections with the starch granules [53,55]. Ye et al. (2018) showed an increase in starch digestion after the removal of total intrinsic protein from rice flour. This suggests that varieties with higher protein content may be beneficial in reducing GI.

There are four types of proteins present in the rice grain: glutelin (60–80%), albumin (4–22%), globulin (5–13%), and prolamin (1–5%). Rice bran contains albumin (24–37%), globulins (15–36%), glutelins (11–38%), and prolamins (2–5%) [61].

In addition to these reports, rice proteins stand out for their health benefits, namely because they are hypoallergenic (gluten free), being widely used in the formulation of baby foods and functional drinks, especially due to their functionality and the fact that they are amenable for improvement by enzymatic hydrolysis [62,63]. Albumin, referred to as a water-soluble protein, having easy digestion and absorption [61,62], stands out in this context. The albumin in rice grain is essentially present in rice bran (3.2–4.9 g/100 g) [64]. It has been highlighted in some studies for its inhibitory effect on starch digesting enzymes (α-amylase), thus contributing to decreasing the foods GI [65]. The rice albumins, with a molecular weight of 14–20 kDa, are recognized as an α-amylase inhibitor [7,65].

2.3. Lipids

Rice bran is a greater source of lipids (15.0–19.7%) than white rice (Table 1). There are two types of lipids present in rice grain: starch lipids, present inside starch granules, and non-starch lipids, outside starch granules [7]. Triacylglycerols are the major non-starch lipids present in the rice grain; free fatty acid and lysophospholipids are the major starch lipids in the rice grain [43]. Starch lipids, although they exist in a smaller proportion, still play an important role in starch functionality and quality, affecting its digestibility by modifying starch swelling, gelatinization, and pasting [66]. These complexes are formed during the synthesis of starch. They are best known for forming complexes with amylose molecules stabilized by hydrogen bounds [43,66], which inhibit the swelling of rice and reduce susceptibility to starch digestive enzymes. The study by Ye et al. (2018) shows that the presence of endogenous lipids has effects on rice flour digestibility. There was an increase in starch digestibility after the removal of the endogenous lipids, confirming the starch-lipid complex interactions [55]. In addition to the importance on starch digestibility, the lipid fraction of the rice grain also contains bioactive compounds (detailed more in Sections 3 and 4) such as γ-oryzanol, tocopherols and tocotrienols, ferulic acid, and triterpene alcohols, with antioxidant properties and effects on diabetes control [67–69].

2.4. Dietary Fiber

Dietary fibers are known as non-digestible carbohydrates and are commonly classified according to their solubility in water, viscosity, or fermentation rate [70]. In soluble fibers, pectin and inulin stand out, whereas, in insoluble fibers, RS, oligosaccharides, cellulose, and hemicellulose are generally predominant [70]. The consumption of dietary fiber has health benefits, namely effects on the control of diseases such as diabetes and hyperlipidemia [43,69,71,72].
Rice bran is a great source of dietary fiber (19–29%), compared with white rice (Table 1). The most common fibers in rice are cellulose, arabinoxylans, and pectic substances [43]. Dietary fiber in rice can be bound with other components, the soluble fibers are complex, with proteins, lipids, and other compounds. Insoluble fibers are not normally easily digested and are fermented in the large intestine, playing an important role. They can confer different rheological properties that influence the quality, sensory, and functional properties [16], and can be used in the development of functional food products. A study by Qureshi et al. (2002) shows improvements in the serum glucose content after consumption of rice bran fiber [71]. Chang et al. (2014) found that there is a correlation between dietary fiber and the glycemic index. Most et al. (2005) reports beneficial effects after the consumption of rice fiber in pos-prandial lipidemia levels [73].

3. Rice Bran Compounds

3.1. γ-Oryzanol

γ-Oryzanol is found mainly in the lipid portion of the rice bran at a concentration ranging from 59.4 to 912.0 mg/100 g [21–24], depending on factors such as the extraction method and rice bran origin. γ-oryzanol is a mixture of ferulate esters (Figure 1), which are formed by esterification of the hydroxyl group of sterols (campesterol, stigmasterol, β-sitosterol) or triterpene alcohols (cycloartanol, cycloartenol, 24-methylenecycloartanol, cyclobranol) with a carboxylic group of ferulic acids [74,75]. Despite that, almost 95% total γ-oryzanol content is essentially composed of four principal ferulate compounds: 24-methylenecycloartanyl ferulate, cycloartenyl ferulate, campesteryl ferulate, and β-sitosteryl [74]. Only a few studies have addressed γ-oryzanol bioavailability. According to Kobayashi et al. (2020), γ-oryzanol can be absorbed in its form or it gives rise to ferulic acid and phytosterols metabolites.

3.2. Phytic Acid

Phytic acid (PA), also known as phosphorus phytate or myo-inositol-1,2,3,4,5,6-hexaphosphate, is an organic acid essentially found in seeds and cereal brans, from where it can be extracted. It represents about 65 to 73% of the total phosphorus content in rice. In the bran, PA is present in greater abundance (90%), varying from 4.0 to 22.5 g/100 g [25,26,28,29]. As for its bioavailability, Schlemmer et al. (2001) demonstrated that, after ingestion, up to about 66% of PA is degraded and absorbed in the stomach and intestine [76]. This process can be accelerated by the presence of phytase enzymes present in the diet or microbial phytases in the large intestine. PA dephosphorylation is metabolized to various inositol phosphate derivatives, which are more easily absorbed [76,77].

3.3. Ferulic Acid

The most abundant phenolic compound found in the endosperm, bran, and whole grain of rice is ferulic acid (FA), corresponding to 56–77% of total phenolic acids. The main function of FA is providing rigidity to the cell wall, with effects on the germination of seeds. FA is composed of an aromatic ring to which a carboxyl group is attached (Figure 1). Also known as 3-methoxy 4-hydroxycinnamic acid, it is present in a concentration range of 1.4–225.4 mg/100 g in rice bran [31]. Owing to its easy absorption and metabolization by the organism, FA derived from rice bran is considered a compound with great nutraceutical potential [17].

3.4. γ-Aminobutyric Acid (GABA)

γ-Aminobutyric acid (GABA) is produced by the decarboxylation of L-glutamic acid by glutamate decarboxylase during the germination process of whole rice, and it is also found in other plants and cereals [78,79]. GABA consists of a chain of four-carbon non-protein with a deprotonated carboxyl group and the protonated amino group at the other end of the chain [80] (Figure 1). Rice bran contains a large amount of glutamic acid, allowing the use of this by-product in the synthesis of GABA by fermentation [34,81,82]. GABA is found essentially in whole rice and rice bran, and its content can be increased with
the germination process of the grain [83]. The amount of GABA in rice bran ranges from 10.7–58.0 mg/100 g (before germination) and 90.0–350.0 mg/100 g (after 10–12 h of rice bran germination) [33–35]. Thus, increased levels of GABA can be obtained by reinforcing the germination status of the grain [83–85].

3.4. γ-Aminobutyric Acid (GABA)

γ-Aminobutyric acid (GABA) is produced by the decarboxylation of L-glutamic acid by glutamate decarboxylase during the germination process of whole rice, and it is also found in other plants and cereals [78,79]. GABA consists of a chain of four-carbon non-protein with a deprotonated carboxyl group and the protonated amino group at the other end of the chain [80] (Figure 1). Rice bran contains a large amount of glutamic acid, allowing the use of this by-product in the synthesis of GABA by fermentation [34,81,82]. GABA is found essentially in whole rice and rice bran, and its content can be increased with the germination process of the grain [83]. The amount of GABA in rice bran ranges from 10.7–58.0 mg/100 g (before germination) and 90.0–350.0 mg/100 g (after 10–12 h of rice bran germination) [33–35]. Thus, increased levels of GABA can be obtained by reinforcing the germination status of the grain [83–85].

3.5. Tocopherols and Tocotrienols (Vitamin E)

Vegetable oils are common sources of tocopherols and tocotrienols (vitamin E), some of which contain predominantly tocopherols (wheat oil), while others contain mainly tocotrienols (rice bran oil) [36,86]. Tocopherols and tocotrienols are a group of antioxidants [36,87,88] present in the unsaponifiable fraction of rice bran oil. They exist in greater quantities in the bran (17.0–22.9 mg/100 g) than in the other fractions of rice [20,36,37]. Vitamin E is composed of a chromanol ring with a carbon side chain that gives it its antioxidant properties by reacting with peroxyl radicals. It is composed of eight different stereoisomers α-, β-, γ-, and δ-tocopherols, with a phytyl side chain, and α-, β-, γ-, and δ-tocotrienols, with an unsaturated isoprenyl side chain (with three double bonds). The biological role of tocopherols and tocotrienols is different depending on their homologous forms, which are distinguished by the number and location of the methyl groups in the chromanol ring [87,88].

Figure 1. Chemical structure of rice bran compounds.
4. Metabolic Mechanisms and Bioactive towards Diabetes

4.1. Glycemic Index of Rice and Effects in Glycemia

Post-prandial glycemia is defined as the blood glucose concentration after a meal and is largely influenced by the GI of foods containing carbohydrates [57,89]. GI is a measure of the glucose response to the intake of a fixed amount of carbohydrates available in the food [57,89] and can be determined in vivo [90]. Determination of GI in vivo is performed in accordance with the standard GI testing protocol, in which foods are tested on fasting individuals, with a reference food (with known glucose concentration). Before and over the time of food digestion, several blood samples are collected, which allows the determination of blood glucose concentration, thus allowing estimation of the food GI. GI can be predicted by in vitro methods assessing the rate of starch hydrolysis [91]. A reference food is also used in the in vitro method, but the process of digestion is done in vitro using a buffer solution containing the sample food and digestive enzymes that hydrolyses complex carbohydrates in sugars (α-amylase and the α-glucosidase). Throughout the digestion process, the glucose formed is determined, which makes it possible to estimate the expected GI.

GI is directly related to starch digestibility and absorption of the compounds generated after starch digestion, being therefore related to factors affecting digestibility or absorption. The rapid- or slow-digestion nature of cooked starch-containing foods has a significant impact on blood glucose concentration [92]. SDS and RS foods, which are indicated by starch being digested gradually or not hydrolysed, are characterized as low GI foods [45]. The presence of bioactive compounds, mainly in the rice bran, can also contribute to the reduction of GI and the valorization of its side-stream product and incorporation into new products. Most studies related to the effect of rice compound intake on the post-prandial glucose decrease were performed using several models (Table 4). It is important to note that these studies evaluated the effects of pure forms of rice bioactive compounds or as supplements in other foods or meals, and they were mostly carried out on animals. Thus, the potential benefits for human health should be extrapolated with caution.

Table 4. Studies on the effect of macronutrients and bioactive rice compounds in the glycemic index of foods, blood glucose and insulin, and oxidative stress.

| Compound          | Model/Dose                                                                 | Effect *                                      | Reference  |
|-------------------|---------------------------------------------------------------------------|----------------------------------------------|------------|
| Rice Proteins     | Wistar rats, diet supplemented with 50–200 mg rice albumin/Kg weight after 15 min of oral starch or glucose administration (1 g/Kg weight) | ↓ Blood glucose                             | [93]       |
|                   | In vitro digestion: native rice protein (12%, pressure cooking 95 °C 30 min) + wheat starch (70%) + digestive enzymes, during 30 min | ↓ RDS content after pressure cooking Native rice protein promotes starch-protein interaction and restricts starch hydration and enzymatic cleavage | [45]       |
| Chinese males, diet: drink rich in carbohydrates (50 g) + rice protein (24 g) during 15, 30, 45, 60, 90, 120, 150, and 180 min | ↓ Post-prandial blood glucose               | [94]       |
|                   | In vitro digestion: rice flour with and without endogenous protein (8.4%) + starch enzymes, during digestion | ↓ Starch digestibility in rice flour with endogenous protein (GI = 92.3 to GI = 88.9) | [55]       |
### Table 4. Cont.

| Compound                | Model/Dose                                                                 | Effect *                                | Reference |
|-------------------------|---------------------------------------------------------------------------|-----------------------------------------|-----------|
| Resistant Starch        | In vitro digestion: cookies with 50% rice flour + 50% RS from de-branched (RSa) or from acid and heat-moisture (RSc) | \(\downarrow\) Starch digestibility reducing cookies estimated GI | [42]      |
|                         | In vivo: healthy and T2DM individuals: meals contained PPB-R-203-derived rice/noodles enriched with RS (10% of starch), 3 days | \(\downarrow\) Blood glucose and insulin \(\downarrow\) Postprandial hyperglycemia in T2DM individuals | [44]      |
| \(\gamma\)-oryzanol     | STZ treated Wistar rats; diet supplemented with oryzanol from rice bran 50 and 100 mg/Kg/day, 8 weeks | \(\downarrow\) Serum glucose \(\downarrow\) Oxidative stress | [18]      |
| Phytic acid (PA)        | Wistar rat diet supplemented with PA at 10 to 13 g diet/day, 3 weeks       | \(\downarrow\) Blood glucose           | [95]      |
|                         | Diabetic Wistar albino rats supplemented with 650 mg PA/kg, 28 days         | \(\downarrow\) Blood glucose           | [96]      |
|                         | C57BL/6N mice; 3 g diet/day contained 0.5% PA, 7 weeks                      | \(\downarrow\) Blood glucose           | [97]      |
|                         | Diabetic KK mice, diet with 0.5–1.0% sodium phytate, 8 weeks                | \(\downarrow\) Blood glucose           | [98]      |
| Ferulic Acid (FA)       | C57BL/KsJ-db/db diabetic mice; diet supplemented with FA from rice, 0.05 g/kg/day, 17 days | \(\downarrow\) Blood glucose \(\uparrow\) Plasma insulin | [99]      |
| \(\gamma\)-Aminobutyric acid (GABA) | C57BL/6 mouse diet supplemented with 2 mg/mL GABA, 20 weeks | \(\downarrow\) Glucose intolerance \(\downarrow\) Fasting blood glucose | [100]     |
| Tocopherols and tocotrienols (vitamin E) | Overweight individuals group supplemented with 800–1200 IU vitamin E/day, 3 months | \(\downarrow\) Fasting plasma glucose and insulin | [101]     |
|                         | Sprague–Dawley diabetic rats; diet with vitamin E extract (1 g/kg weight), 12 weeks | \(\downarrow\) Blood glucose           | [102]     |

* \(\uparrow\)** means increase; \(\downarrow\)** means decrease.

4.2. \(\alpha\)-Amylase and \(\alpha\)-Glucosidase Inhibition

Inhibition of \(\alpha\)-glucosidase and \(\alpha\)-amylase is another strategy to control hyperglycemia [103]. Complex carbohydrates reaching the small intestine cannot be directly absorbed by enterocytes of the epithelium; they need to be first degraded by the glycohydrolases \(\alpha\)-amylase and \(\alpha\)-glucosidase. Inhibitors of these enzymes delay the increase of glucose concentration in the small intestine and efficiently promotes apical glucose transporters (GLUT2 and SGLT1) insertion, preventing the increase of blood glucose levels [104]. Compounds inhibiting these enzymes may contribute to the reduction of GI of carbohydrate-containing foods, allowing the design of healthy products for diabetes control.
α-Amylases (EC 3.2.1.1) are enzymes responsible for the hydrolysis of the α-(1,4)-glycosidic bonds of starch forming dextrins. There are two types of α-amylases present in mammals. The salivary α-amylase is active during chewing in the mouth and acts at a higher pH, being inactive in the stomach. The pancreatic α-amylase acts in the first stage of carbohydrates digestion in the small intestine [105].

α-Glucosidases (EC 3.2.1.20) are a group of enzymes responsible for the hydrolysis of non-reducing terminal α-(1,4)-glycosidic bonds of oligosaccharides and polysaccharides [65] in monosaccharides such as glucose. These enzymes, including trehalase, lactase, maltase-glucoamylase complex, and sucrase-isomaltase complex, are bound to the wall/edge of the small intestine and degrade the dextrins resulting from the digestion of amylase before the absorption of glucose by the intestine wall. The studies addressing the effect of rice compounds on α-amylase and α-glucosidase activities are summarized in Table 5.

### Table 5. Effect of macronutrients and bioactive rice compounds in α-amylase and α-glucosidase activities.

| Compound            | Model/Dose                                                                 | Effect                                                                 | Reference |
|---------------------|---------------------------------------------------------------------------|----------------------------------------------------------------------|-----------|
| Rice Proteins       | Protein hydrolysates from rice bran (cultivar Reiziq); 10 mg/mL + in vitro enzyme preparations + 1% starch solution, 240 min | High inhibition of starch enzymes activities by albumin and glutelin | [65]      |
| γ-oryzanol          | 40 μL α-amylase 50 U/mg + 0.5 mL γ-oryzanol + 40 μL of starch 1%; 100 μL α-glucosidase 50 U/mg + 5 mg γ-oryzanol, 30 min | Inhibition of α-amylase (IC₅₀ = 0.78 mg/mL) and α-glucosidase (IC₅₀ = 0.81 mg/mL) * | [106]     |
| Phytic acid (PA)    | 1 U/mL α-amylase + 0.25–8 μg PA/mL, 3 min; 5–100 μg PA/mL + ~0.1 mL α-glucosidase + starch solution 0.5%, 60 min | Inhibition of α-amylase (IC₅₀ = 1.2 μg/mL) and α-glucosidase (IC₅₀ = 3.2 μg/mL) * | [96]      |
| Ferulic Acid (FA)   | In vitro: 100 mg Rat intestinal acetone powder + 10 μL maltase or 40 μL sucrase + 0–1 mM FA, 30–60 min | Inhibition of α-glucosidase (IC₅₀ = 0.79 mM) and intestinal maltase and sucrase (IC₅₀ = 0.45 mM) * | [107]     |
| γ-Aminobutyric acid (GABA) | 20 μL α-glucosidase from baker’s yeast + 20 μL FA, 30 min | Inhibition of α-glucosidase (IC₅₀ = 0.8 mg/mL) * | [99]      |
|                     | 50 μL α-glucosidase + 0.2 U/mL + 50 μL cell-free extract from yeasts containing GABA (86.2–179.2 μL/mL), 30 min | Anti-hyperglycemic effect High inhibition of α-glucosidase (up to 72.3%) | [108]     |

*IC₅₀-concentration at which a compound exerts half of its maximal inhibitory effect.

### 4.3. Modulation of Glucose Transporters

Glucose transport is one of the main nutrient uptake systems in intestinal cells. In fact, intestinal glucose transport and absorption are fundamental processes to understand postprandial fluctuations in blood glucose concentration with implications in diabetes control. It is catalyzed by a group of glucose transporters (GLUT) and sodium-coupled glucose co-transporters (SGLT) [109]. The GLUT family of transporter proteins is composed of GLUT1-12,14, GLUT1 to 4 being the most studied. In addition, there is the myo-inositol
transporter (HMIT). SGLTs and GLUTs are responsible for the transport of monosaccharides through the lipid bilayer of the plasma membrane in eukaryotic cells. These transporters in the intestine can be classified according to their affinity and capacity to transport glucose into blood (GLUT2) and enterocytes (SGLT1 and GLUT2) [110]. Although transport by GLUT2 is facilitated, transport by SGLT1 is active via the Na/K-pump, which provides energy and maintains the sugar gradient [109].

Before a meal, when the sugar concentration in the lumen and blood is low, the only active transporter is SGLT1, with GLUT2 being present in a very low concentration. After a meal, when the glucose concentration in the lumen is high, GLUT2 is activated in the apical enterocyte membrane [110], increasing glucose uptake ~3-fold. Before absorption in the small intestine by enterocytes, carbohydrates are digested in monosaccharides that are transported by SGLT1, GLUT2, and GLUT5 (for fructose) [109]. GLUT2 is responsible for 75% of total glucose absorption [104]. Thus, activation of GLUT2 is affected by the sugar content of the diet. In diabetes, there is an increase in intestinal glucose absorption, due in large part to the overexpression of GLUT2 and SGLT1 transporters [104]. Thus, diet supplements inhibiting glucose absorption through SGLT1 and GLUT2 can potentially be used for blood glucose regulation and insulin secretion therapies [104,110–112]. Table 6 summarizes in vivo and in vitro studies supporting the modulation of GLUT2 and SGLT1 expression by rice compounds.

**Table 6.** Effect of macronutrients and bioactive rice compounds in the modulation of SGLT1 and GLUT2.

| Compound          | Model/Dose                                                                 | Effect                                      | Reference |
|-------------------|---------------------------------------------------------------------------|---------------------------------------------|-----------|
| Rice Proteins     | Intestinal STC-1 cells with 100 µg of tripsin-digested rice albumin/mL, 48 h | Suppressed SGLT1                           | [113]     |
| Phytic acid (PA)  | Piglets (Yorkshire-Landracex Duroc) supplemented with 2 g PA or Na phytate/1 kg diet, 10 days | ↓ Crypt depth in the jejunum ↓ SGLT1 expression in the duodenum, jejunum, and ileum ↓ Nutrient utilization in pigs, which is involved in glucose and Na absorption | [114]     |
| Ferulic acid (FA) | Caco-2 cells, 0–0.1 mg/mL FA, 15 min; *Xenopus laevis* oocytes, 100–300 µM FA, 30 min | ↓ Glucose uptake in Caco-2 cells Block glucose uptake in oocytes ≥100 µM ↓ GLUT2 in oocytes | [115]     |

"↑" means increase; "↓" means decrease.

**4.4. Other Molecular Mechanisms Associated with Diabetes**

Diabetes is a multi-factorial disorder and, in addition to the mechanisms mentioned above, other molecular pathways contribute to disease onset and progression, in particular those related to pancreatic β-cell dysfunction [116–118]. The intracellular aggregation of Islet amyloid polypeptide (IAPP) and the accumulation of extracellular amyloid deposits in the vicinity of pancreatic β-cells, which have been found in over 95% of T2DM patients [119], are some of these pathways. In response to glucose stimulus, β-cells secrete insulin and IAPP, or amylin. IAPP is a highly amyloidogenic hormone that, under physiological conditions, contributes to regulating glucose levels by inhibiting insulin and glucagon secretion, also controlling adiposity and satiation [120]. In T2DM, cells become resistant to insulin, leading to the dysregulation of glucose metabolism [121]. As a compensatory mechanism, there is an increase of β-cell activity to produce more insulin. Increased activity of β-cells leads to the overproduction of IAPP, which in turn triggers IAPP intracellular oligomerization and the accumulation of extracellular amyloid plaques [122,123].
The impact of IAPP intracellular oligomerization affecting fundamental β-cell functions [124], the deposition of IAPP fibrils between β-cells and capillary endothelial cells, likely impairs glucose and nutrients flow, favoring cell death and interfering with insulin secretion [124,125]. In addition, the high demand for insulin/IAPP production by β-cells trigger endoplasmic reticulum (ER) stress causing progressive dysfunction and ultimately the death of these cells [118]. Thus, strategies aimed at improving function or decreasing the death of β-cells are currently under investigation as a means to delay disease onset and progression. Table 7 summarizes the in vivo and in vitro studies, pointing out the potential of rice bioactivities as protective compounds against these pathological mechanisms.

4.5. Highlight on Rice Major Bioactive Compounds towards Diabetes

4.5.1. γ-Oryzanol

γ-oryzanol exerts a plethora of bioactivities, antioxidant and hypocholesterolemic properties especially, and it has been mainly explored in terms of cosmetics, pharmaceuticals, and as food supplements [16,125]. The γ-oryzanol activity related to diabetes is associated with its antioxidant and hypocholesterolemic properties [18,126]. The latter comes from its ability to inhibit the hydrolytic function of the enzyme cholesterol esterase (CEase), essential to produce free cholesterol in the lumen. As for its potential antioxidant activity, the component of γ-oryzanol standing out with the greatest antioxidant activity in vitro is 24-methylenecycloartanyl [74,127,128], due to the presence of a hydroxyl group on the phenolic ring [129]. It remains to be seen whether γ-oryzanol concentrations reaching internal tissues are sufficient to exert this potential activity. γ-oryzanol antioxidant properties are also mediated through the activation of the antioxidant enzymes, including superoxide dismutase, catalase, and glutathione peroxidase, responsible for the neutralization of reactive oxidative species (ROS) [126], as determined by in vivo studies in mice [18,130–133]. In fact, the administration of γ-oryzanol reduces blood glucose levels as well as the symptoms of diabetic neuropathy in diabetic rats [18]. The studies evaluating γ-oryzanol antioxidant and potential effects in the control of diabetes are compiled in Tables 4–7.

| Table 7. Effect of bioactive rice compounds against pathological mechanisms associated with diabetes. |
|---|---|---|---|
| **Source** | **Model/Dose** | **Effect** | **Reference** |
| γ-oryzanol | C57BL/6J mouse, diet supplemented with oryzanol 320 µg/g weight/day, 13 weeks | ↓ ER stress in pancreatic β-cells; ↓ Pancreatic islet dysfunction, ↑ Protection of β-cells against apoptosis | [118] |
| Ferulic acid (FA) | Cell-free, human amylin peptide + 10–40 µM FA, 192 h | ↓ IAPP amyloid formation by 27.7% to 22.6% | [134] |
| γ-Aminobutyric acid (GABA) | CD1 mice + 2 injections of 20 µmol GABA/mouse during 48 h; INS-1 cells challenged with streptozotocin (STZ) (15 mM, 24 h) + 1, 10, 100 µM of GABA | ↑ Islet cell function, ↑ Protection of β-cell from apoptosis | [116] |
| | CD1 or C57 mouse, supplemented with 6 mg GABA/mL, 10 weeks | ↑ β-cell proliferation, ↑ Insulin secretion | [117] |
| Tocopherols and tocotrienols (vitamin E) | C3H/AnLCS®CSa mouse induced with alloxan and supplemented with 50 mg α-tocopherol/100 g diet, 14 weeks | ↑ Insulin secretion, ↓ Apoptosis caused by oxidative stress | [19] |

“↑” means increase; “↓” means decrease.
4.5.2. Phytic Acid

Despite being considered an anti-nutrient, due to the formation of complexes (with calcium and magnesium) during the digestion process, PA has been studied for its hypolipidemic and antioxidant effects, the latter mainly through the suppression of oxidative reactions catalyzed by Fe [28]. PA benefits for diabetes are related to the prevention of hyperglycemia through the reduction of starch digestibility [135,136]. In fact, animal studies show the reduction of blood glucose when PA is added to diet [11,95–98,137,138]. It is also thought that PA reduces starch digestion rate, binding to the salivary and pancreatic amylase enzyme through phosphate bonds or by binding with minerals that catalyze the activity of amylase, such as calcium, restricting its activity [97]. The studies evaluating the potential effects of PA in the control of diabetes are compiled in Tables 4–7.

4.5.3. Ferulic Acid

The antioxidant capacity of FA seems to be related to the presence of electron donor groups in the benzene ring, allowing FA to end the chain reactions of free radicals, and to ROS elimination [129,139] by increasing the activity of antioxidant enzymes [17,133]. FA also stands out for its effects in diabetes control [140] at various levels: reducing blood glucose through inhibition of $\alpha$-glucosidase [95] and improving insulin secretion in diabetic rat models [141] and in pancreatic cells [142]. The main FA effects towards diabetes are summarized in Tables 4–7.

4.5.4. $\gamma$-Aminobutyric Acid (GABA)

GABA is a neurotransmitter found in the central nervous system with two important functions: a tranquilizer and a hypotensive [78,80]. Protective actions of GABA have been associated with the prevention of Alzheimer’s disease [143], reduction of blood pressure [144], and prevention of diabetes [107]. As for its antidiabetic properties, GABA is known to control insulin secretion by pancreatic $\beta$-cells [116] through glucagon inhibition. In addition, GABA inhibits glucagon secretion by promoting the conversion of $\alpha$-cells into $\beta$-cells, thereby contributing to the increase of $\beta$-cell mass and insulin production [116,145,146]. Overall, studies have shown that regular consumption of GABA-rich foods can contribute to the increase of insulin secretion and decrease blood glucose [100,108]. The studies evaluating GABA’s potential effects in the control of diabetes are compiled in Tables 4–7.

4.5.5. Tocopherols and Tocotrienols (Vitamin E)

The potential effect of vitamin E in diabetes control is related to its antioxidant properties against ROS and nitrous compounds affecting $\beta$-cell function [147–149]. Diet supplementation for 3 months with vitamin E decreased plasma glucose and peroxide levels and improved insulin levels in overweight individuals [101]. Vitamin E extracts also showed beneficial effects for reducing the blood glucose levels of diabetic rats [102]. These fat-soluble compounds can decrease insulin resistance and improve glucose metabolism in diabetic rats by modulation of peroxisome proliferator-activated receptors and regulation of energy metabolism [150]. The studies evaluating the potential effects of tocopherols and tocotrienols in the control of diabetes are compiled in Tables 4 and 7.

5. Conclusions

Rice components, especially macronutrients (starch, proteins) and the compounds present in bran ($\gamma$-oryzanol, phytic acid, ferulic acid, $\gamma$-aminobutyric acid, tocopherols, and tocotrienols) have been pointed to as having potential bioactive effects that could be beneficial for diabetes prevention and control. The protective effects of rice bran constituents are mostly related to the reduction of food GI, partially due to the inhibition of $\alpha$-amylase and $\alpha$-glucosidase (vitamin E is an exception), with implications in the reduction of blood glucose. Ferulic acid stands out as having bioactive effects towards several diabetes pathological processes, including the potential inhibition of protein aggregation.
and amyloidogenesis. Phytic acid, ferulic acid, and rice proteins (albumin) are suggested to modulate the activity of glucose transporters, whereas $\gamma$-oryzanol, $\gamma$-aminobutyric acid, tocopherol, and tocotrienol bioactivities are associated with the attenuation of $\beta$-cell dysfunction in the pancreas. Despite evidences of the positive effects of rice macronutrients and bran bioactive compounds on diabetes, further studies are needed to support the exploitation of rice compounds in diabetes control.

Author Contributions: Conceptualization, C.P., R.M., and C.B.; methodology, C.P., V.M.L., R.M. and C.B.; resources, C.B.; writing—original draft preparation, C.P. and C.B.; writing—review and editing, V.M.L., R.M. and C.B.; project administration, C.B. All authors have read and agreed to the published version of the manuscript.

Funding: The study was funded by FCT, Foundation for Science and Technology (Portugal), through PhD grant number 2020.09555BD to C.P., and funded by project TRACE-RICE—Tracing rice and valorizing side streams along Mediterranean blockchain, grant no. 1934, of the PRIMA Programme, supported under Horizon 2020, the European Union’s Framework Programme for Research and Innovation, and Research Unit, UIDB/04551/2020 (GREEN-IT, Bioresources for Sustainability). The study was also funded by FCT through Scientific Employment Stimulus contract CEEC/04567/CBIOS/2020 and project PTDC/BLA-MOL/31104/2017 to R.M. and projects UIDB/04567/2020 and UIDP/04567/2020 to CBIOS.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. International Diabetes Federation (IDF). What is diabetes? In Diabetes Atlas, 9th ed.; IDF: Brussels, Belgium, 2019; Volume 1, pp. 10–22.
2. Eggersdorfer, M.; Kraemer, K.; Cordaro, J.B.; Fanzo, J.; Gibney, M.; Kennedy, E.; Labrique, A.; Steffen, J. Diet and $s$: An urgent need for new paradigms. In Good Nutrition: Perspectives for the 21st Century; Karger: Basel, Switzerland, 2016; pp. 105–118.
3. Kubota, M.; Watanabe, R.; Kabasawa, H.; Iino, N.; Saito, A.; Kumagai, T.; Kadowaki, M. Rice protein ameliorates the progression of diabetic nephropathy in Goto-Kakizaki rats with high-sucrose feeding. Br. J. Nutr. 2013, 110, 1211–1219. [CrossRef]
4. Prakash, S. Role of Human Serum Albumin and Oxidative Stress in Diabetes. J. Appl. Biotechnol. Bioeng. 2017, 3, 281–285. [CrossRef]
5. Cavan, D.; Fernandes, J.R.; Makarof, L.; Ogurtsova, K.; Webber, S. IDF Diabetes Atlas, 7th ed.; International Diabetes Federation: Brussels, Belgium, 2015; pp. 12–19.
6. Hu, J.; La Vecchia, C.; Augustin, L.S.; Negri, E.; de Groh, M.; Morrison, H. Glycemic index, glycemic load and cancer risk. Ann. Oncol. 2013, 24, 245–251. [CrossRef] [PubMed]
7. Champagne, E.T. Rice: Chemistry and Technology, 3rd ed.; AACC International Press: Washington, DC, USA; Department of Agriculture, Agricultural Research Service, Southern Regional Research Center: New Orleans, LA, USA, 2004; pp. 77–190.
8. Juliano, B.O.; Tuaño, A.P. Gross structure and composition of the rice grain. In Rice, Chemistry and Technology, 4th ed.; AACC International Press: Washington, DC, USA, 2019; pp. 31–53.
9. Faid, S.M.A.E.F. The beneficial effects of brown rice and its bran as natural antioxidants and lowering hyperglycemic in Albino rats. Middle East J. Appl. 2015, 5, 281–289. [CrossRef]
10. Mohan, V.; Spiegelman, D.; Sudha, V.; Gayathri, R.; Hong, B.; Praseena, K.; Anjana, R.M.; Wedick, N.M.; Arumugam, K.; Malik, V.; et al. Effect of brown rice, white rice, and brown rice with legumes on blood glucose and insulin responses in overweight Asian Indians: A randomized controlled trial. Diabetes Technol. Ther. 2014, 16, 317–325. [CrossRef] [PubMed]
11. Panlasigui, L.; Thompson, L. Blood glucose lowering effects of brown rice in normal and diabetic subjects. Int. J. Food Sci. Nutr. 2006, 57, 151–156. [CrossRef]
12. Essa, N.M.; Ling, T.B.; Peng, L.S. By-products of rice processing: An overview of health benefits and applications. J. Rice Res. 2013, 1, 1–11.
13. Mohapatra, D.; Bal, S. Effect of degree of milling on specific energy consumption, optical measurements and cooking quality of rice. J. Food Eng. 2007, 80, 119–125. [CrossRef]
14. Sivamaruthi, B.S.; Kesika, P.; Chaiyasut, C. A comprehensive review on anti-diabetic property of rice bran. Asian Pac. J. Trop. Biomed. 2018, 8, 79–84. [CrossRef]
15. Bhat, F.M.; Riar, C.S.; Sreesuriyachan, P.; Sommano, S.R.; Chaiyaso, T.; Prom-u-Thai, C. Status of Bioactive Compounds from Bran of Pigmented Traditional Rice Varieties and their Scope in Production of Medicinal Food with Nutraceutical Importance. Agron. J. 2020, 10, 1817. [CrossRef]
16. Park, H.-Y.; Leeb, K.-W.; Choi, H.-D. Rice bran constituents: Immunomodulatory and therapeutic activities. *Food Funct.* **2017**, *8*, 935–943. [CrossRef] [PubMed]

17. Perez-Temero, C.; Sotomayor, M.A.; Herrera, M.D. Contribution of ferulic acid, γ-oryzanol and tocotrienols to the cardiometabolic protective effects of rice bran. *J. Funct. Foods* **2017**, *32*, 58–71. [CrossRef]

18. Ghatak, S.B.; Panchal, S.S. Protective effect of oryzanol isolated from crude rice bran oil in experimental model of diabetic neuropathy. *J. Pharmacol.* **2012**, *22*, 1092–1103. [CrossRef]

19. Takemoto, K.; Doib, W.; Masuoka, N. Protective effect of vitamin E against alloxan-induced mouse hyperglycemia. *Biochim. Biophys. Acta (BBA) Mol. Basis Dis.* **2016**, *1862*, 647–650. [CrossRef] [PubMed]

20. Jeng, T.L.; Shih, Y.J.; Ho, P.T.; Lai, C.C.; Lin, Y.W.; Wang, C.S.; Sung, J.M. γ-Oryzanol, tocol and mineral compositions in different grain fractions of giant embryo rice mutants. *J. Sci. Food Agric.* **2012**, *92*, 1468–1474. [CrossRef] [PubMed]

21. Castanho, A.; Lageiro, M.; Calhelha, R.; Ferreira, I.C.F.R.; Junior, A.M.M.; Canan, C. Rice and rice bran from different exotic rice varieties. *J. Funct. Foods* **2019**, *10*, 2382–2389. [CrossRef] [PubMed]

22. Massarolo, K.C.; Ribeiro, A.C.; Furlong, E.B.; Soares, L.A.S. Characterization of antioxidant properties of γ-oryzanol from bran of different rice varieties. *J. Funct. Foods* **2019**, *10*, 2382–2389. [CrossRef] [PubMed]

23. Pokkanta, P.; Sookwong, P.; Tanang, M.; Setchaiyan, S.; Boontakham, P.; Mahatheeranont, S. Simultaneous determination of tocols, γ-oryzanol, phytosterols, squalene, cholecalciferol and phylloquinone in rice bran and vegetable oil samples. *Food Chem.* **2019**, *271*, 630–638. [CrossRef] [PubMed]

24. Wanyo, P.; Kaewseejan, N.; Meeso, N.; Sangwichaiyan, S.; Boontakham, P.; Mahatheeranont, S. Simultaneous determination of tocols, γ-oryzanol, phytosterols, squalene, cholecalciferol and phylloquinone in rice bran and vegetable oil samples. *Food Chem.* **2019**, *271*, 630–638. [CrossRef] [PubMed]

25. Ren, X.-L.; Liu, Q.-L.; Fu, H.-W.; Wu, D.-X.; Shu, Q.-Y. Density alteration of nutrient elements in rice grains of a low phytate mutant. *Food Chem.* **2007**, *102*, 1400–1406. [CrossRef]

26. Kalschne, D.L.; Silva-Buzanello, R.A.; Byler, A.P.; Scremin, F.R.; Junior, A.M.M.; Canan, C. Rice and rice bran from different cultivars: Physicochemical, spectroscopic, and thermal analysis characterization. *Food Sci. Technol.* **2020**, *41*, 3081–3092. [CrossRef]

27. Wang, K.M.; Wu, J.G.; Li, G.; Zhang, D.P.; Yang, Z.W.; Shi, C.H. Distribution of phytic acid and mineral elements in three indica rice (Oryza sativa L.) cultivars. *J. Cereal Sci.* **2011**, *54*, 116–121. [CrossRef]

28. Canan, C.; Cruz, F.T.L.; Delaroza, F.; Casagrande, R.; Sarmento, C.P.M.; Shimokomaki, M.; Ida, E.I. Studies on the extraction and purification of phytic acid from rice bran. *J. Food Compos. Anal.* **2011**, *24*, 1057–1063. [CrossRef]

29. Pereira, C.; Castanho, A.; Lageiro, M.; Brites, C. Rice phytic acid quantification and assessment of their inhibitory effect against α-amylase activity. In *Proceedings of the Simpósio INIAV para a Segurança Alimentar “Rumo à Alimentação do Futuro”*, 1ª edição, Vila do Conde, Portugal, 29 November 2019.

30. Finocchiaro, F.; Ferrari, B.; Gianinetti, A.; Dall’Asta, C.; Galaverna, G.; Scassina, F.; Pellegrini, N. Characterization of antioxidant compounds of red and white rice and changes in total antioxidant capacity during processing. *Mol. Nutr. Food Res.* **2007**, *51*, 1006–1019. [CrossRef]

31. Zhou, Z.; Robards, K.; Helliswell, S.; Blanchard, C. The distribution of phenolic acids in rice. *Food Chem.* **2004**, *87*, 401–406. [CrossRef]

32. Hayat, A.; Jahangir, T.M.; Khuhawar, M.Y.; Alamgir, M.; Siddiqui, A.J.; Musharraf, S.G. Simultaneous HPLC Determination of Gamma Amino Butyric Acid (GABA) and Lysine in Selected Pakistani Rice Varieties by Pre-column Derivatization with 2-Hydroxynaphthaldehyde. *J. Cereal Sci.* **2014**, *60*, 356–360. [CrossRef]

33. Eamarjharn, A.; Theerakulkait, C.; Thanachasai, S. Effect of incubation time, buffer type and concentration on gamma-aminobutyric acid (GABA) production using Khao Dawk Mali 105 rice bran. *Agric. Nat. Resour.* **2016**, *75*, 935–943. [CrossRef] [PubMed]

34. Lü, Y.; Zhang, H.; Yao, H. Enzymatic Production of γ-Aminobutyric Acid Using Rice Bran. *Adv. Mater. Res.* **2012**, *586*, 85–91. [CrossRef]

35. Oh, S.-J.; Kim, H.S.; Lim, S.-T.; Reddy, C.K. Enhanced accumulation of gamma-aminobutyric acid in rice bran using anaerobic incubation with various additives. *Food Chem.* **2019**, *271*, 187–192. [CrossRef]

36. Rohrer, C.; Siebenmorgen, T. Nutraceutical concentrations within the bran of various rice kernel thickness fractions. *Biosyst. Eng.* **2004**, *88*, 453–460. [CrossRef]

37. Schramm, R.; Abadie, A.; Hua, N.; Xu, Z.; Lima, M. Fractionation of the rice bran layer and quantification of vitamin E, oryzanol, protein, and rice bran saccharides. *J. Biol. Eng.* **2007**, *1*, 1–9. [CrossRef] [PubMed]

38. Chang, U.J.; Hong, Y.H.; Jung, E.Y.; Suh, H.J. Rice and the glycemic index. In *Wheat and Rice in Disease Prevention and Health*, Academic Press: Cambridge, MA, USA, 2014; Volume 27, pp. 357–363.

39. Kaur, B.; Ranawana, V.; Henry, J. The Glycemic Index of Rice and Rice Products: A Review, and Table of GI Values. *Crit. Rev. Food Sci. Nutr.* **2016**, *56*, 215–236. [CrossRef] [PubMed]

40. Atkinson, F.S.; Brand-Miller, J.C.; Foster-Powell, K.; Buyken, A.E.; Goletzke, J. International tables of glycemic index and glycemic load values 2021: A systematic review. *Am. J. Clin. Nutr.* **2021**, *1–8*. [CrossRef]

41. Agama-Acevedo, E.; Islas-Hernández, J.J.; Pacheco-Vargas, G.; Osorio-Díaz, P.; Bello-Pérez, L.A. Starch digestibility and glycemic index of cookies partially substituted with unripe banana flour. *LWT Food Sci. Technol.* **2012**, *46*, 177–182. [CrossRef]

42. Giuberti, G.; Marti, A.; Fortunati, P.; Gallo, A. Gluten free rice cookies with resistant starch ingredients from modified waxy rice starches: Nutritional aspects and textural characteristics. *J. Cereal Sci.* **2017**, *76*, 157–164. [CrossRef]
43. Khatan, A.; Waters, D.L.E.; Liu, L. A review of rice starch digestibility: Effect of composition and heat-moisture processing. Starch 2019, 71, 9–10. [CrossRef]
44. Lin, C.-H.; Chang, D.-M.; Wu, D.-J.; Peng, H.-Y.; Chuang, L.-M. Assessment of Blood Glucose Regulation and Safety of Resistant Starch Formula-Based Diet in Healthy Normal and Subjects with Type 2 Diabetes. Medicine 2015, 94, e1332. [CrossRef]
45. López-Barón, N.; Gu, Y.; Vasanthan, T.; Hoover, R. Plant proteins mitigate in vitro wheat starch digestibility. Food Hydrocoll. 2017, 69, 19–27. [CrossRef]
46. Nugent, A. Health properties of resistant starch. Nutr. Bull. 2005, 30, 27–54. [CrossRef]
47. Yi, D.; Maike, W.; Yi, S.; Xiaoil, S.; Dianxing, W.; Wenjian, S. Physicochemical Properties of Resistant Starch and Its Enhancement Approaches in Rice. Rice Sci. 2021, 28, 31–42. [CrossRef]
48. Alcazar-Alay, S.C.; Metreles, M.A.A. Physicochemical properties, modifications and applications of starches from different botanical sources. Food Sci. Technol. 2015, 35, 215–236. [CrossRef]
49. Deepa, G.; Singh, V.; Naidu, K.A. A comparative study on starch digestibility, glycemic index and resistant starch of pigmented (‘Njavara’ and ‘Jyothi’) and a non-pigmented (‘IR 64’) rice varieties. J. Food Sci. Technol. 2010, 47, 644–649. [CrossRef] [PubMed]
50. Frei, M.; Siddhuraju, P.; Becker, K. Studies on the in vitro starch digestibility and the glycemic index of six different indigenous rice cultivars from the Philippines. Food Chem. 2003, 83, 395–402. [CrossRef]
51. Hu, P.; Zhao, H.; Duan, Z.; Linlin, Z.; Wu, D. Starch digestibility and the estimated glycemic score of different types of rice differing in amylose contents. J. Cereal Sci. 2004, 40, 231–237. [CrossRef]
52. Kumar, A.; Sahoo, U.; Baisakha, B.; Okpani, O.A.; Ngankhham, C.; Basak, N.; Kumar, G.; Sharma, S.G. Resistant starch could be decisive in determining the glycemic index of rice cultivars. J. Cereal Sci. 2018, 79, 348–353. [CrossRef]
53. Toutouanj, M.R.; Farahnaky, A.; Santhakumar, A.B.; Oli, P.; Butardo, V.M.; Blanchard, C.L. Intrinsic and extrinsic factors affecting rice starch digestibility. Trends Food Sci. Technol. 2019, 88, 10–22. [CrossRef]
54. Lian, X.; Zhu, W.; Wen, Y.; Li, L.; Zhao, X. Effects of soy protein hydrolysates on maize starch retrogradation studied by IR spectra and ESI-MS analysis. Int. J. Biol. Macromol. 2016, 93, 135–145. [CrossRef]
55. Ye, J.; Hu, X.; Luo, S.; McClements, D.J.; Liang, L.; Liu, C. Effect of endogenous proteins and lipids on starch digestibility in rice flour. Food Res. Int. 2018, 106, 404–409. [CrossRef]
56. Anacleto, R.; Badoni, S.; Parween, S.; Butardo, V.M.; Misra, G.; Cuevas, R.P.; Mallillin, A.C.; Acuin, C.; et al. Integrating a genome-wide association study with a large-scale transcriptome analysis to predict genetic regions influencing the glycaemic index and texture in rice. Plant Biotechnol. J. 2019, 17, 1261–1275. [CrossRef] [PubMed]
57. Jenkins, D.J.; Kendall, C.W.; Augustin, L.S.; Franceschi, S.; Hamidi, M.; Marchie, A. Glycemic index: Overview of implications in health and disease. Am. J. Clin. Nutr. 2002, 76, 266–273. [CrossRef]
58. Augustin, L.S.; Franceschi, S.; Jenkins, D.J.A.; Kendall, C.W.C.; La Vecchia, C. Glycemic index in chronic disease: A review. Eur. J. Clin. Nutr. 2002, 56, 1049–1071. [CrossRef]
59. Hu, R.J.-C.; Lu, S.; Chang, Y.; Chiang, W. Effects of added water and retrogradation on starch digestibility of cooked rice flours with different amylose content. J. Cereal Sci. 2015, 61, 1–7. [CrossRef]
60. Kong, X.; Chen, Y.; Zhu, P.; Sui, Z.; Corke, H.; Bao, J. On the relationships among genetic, structural and functional properties of rice starch. J. Agric. Food Chem. 2015, 63, 6241–6248. [CrossRef] [PubMed]
61. Hoogenkamp, H.; Kumagai, H.; Wanasundara, J.P.D. Rice protein and rice protein products. In Sustainable Protein Sources; Academic Press: Cambridge, MA, USA, 2017; Volume 3, pp. 47–65.
62. Amagliani, L.; O’Regan, J.; Kelly, A.L.; O’Mahony, J.A. The composition, extraction, functionality and applications of rice proteins: A review. Trends Food Sci. Technol. 2017, 64, 1–12. [CrossRef]
63. Zheng, Y.; Gao, N.; Wu, J.; Yin, B. Rice bran protein: Extraction, nutraceutical properties, and potential applications. In Rice bran and Rice Bran Oil; AOCS Press: Urbana, IL, USA, 2019; Volume 11, pp. 271–293.
64. Adebiyi, A.P.; Adebiyi, A.O.; Hasegawa, Y.; Ogawa, T.; Muramoto, K. Isolation and characterization of protein fractions from deoiled rice bran. Eur. Food Res. Technol. 2009, 288, 391–401. [CrossRef]
65. Uraipong, C.; Zhao, J. In vitro digestion of rice bran proteins produces peptides with potent inhibitory effects on alpha-glucosidase and angiotensin I converting enzyme. J. Sci. Food Agric. 2015, 95, 758–766. [CrossRef] [PubMed]
66. Luo, J.; Liu, L.; Konik-Rose, C.; Tian, L.; Singh, S.; Howitt, C.A.; Li, Z.; Liu, Q. Down-Regulation of FAD2-1 Gene Expression Alters Lysophospholipid Composition in the Endosperm of Rice Grain and Influences Starch Properties. Foods 2021, 10, 1169. [CrossRef]
67. Ali, A.; Devarajan, S. Nutritional and health benefits of rice bran oil. In Brown Rice; Springer: Cham, Switzerland, 2017; Chapter 9; pp. 135–158.
68. Lu, X.N.; Wang, J.; AL-Oadiri, H.M.; Ross, C.F.; Powers, J.R.; Tang, J.M.; Rasco, B.A. Determination of total phenolic content and antioxidant capacity of onion (Allium cepa) and shallot (Allium Oschaninii) using infrared spectroscopy. Food Chem. 2011, 129, 637–644. [CrossRef]
69. Sohail, M.; Rakha, A.; Butt, M.S.; Iqbal, M.J.; Rashid, S. Rice Bran Nutraceutics: A Comprehensive Review. Crit. Rev. Food Sci Nutr. 2017, 57, 3771–3780. [CrossRef]
70. Weickert, M.O.; Pfeiffer, A.F.H. Metabolic Effects of Dietary Fiber Consumption and Prevention of Diabetes. Am. Soc. Nutr. J. Nutr. 2008, 138, 439–442. [CrossRef]
71. Qureshi, A.A.; Sami, S.A.; Khan, F.A. Effects of stabilized rice bran, its soluble and fiber fractions on blood glucose levels and serum lipid parameters in humans with diabetes mellitus Types I and II. J. Nutr. Biochem. 2002, 13, 175–187. [CrossRef]
72. Ullah, U.; Khalil, A.A.; Shaukat, F.; Song, Y. Sources, Extraction and Biomedical Properties of Polysaccharides. Foods 2019, 8, 304. [CrossRef]
73. Most, M.M.; Tulley, R.; Morales, S.; Lefevre, M. Rice bran oil, not fiber, lowers cholesterol in humans. Am. J. Clin. Nutr. 2005, 81, 64–68. [CrossRef]
74. Xu, Z.; Hua, N.; Godber, J.S. Antioxidant Activity of Tocopherols, Tocotrienols, and γ-Oryzanol Components from Rice Bran against Cholesterol Oxidation Accelerated by 2,2’-Azobis(2-methylpropionamide) Dihydrochloride. J. Agric. Food Chem. 2001, 49, 2077–2081. [CrossRef]
75. Yu, S.; Nehus, Z.T.; Badger, T.M.; Fang, N. Quantification of Vitamin E and γ-Oryzanol Components in Rice Germ and Bran. J Agric. Food Chem. 2007, 5, 7308–7313. [CrossRef] [PubMed]
76. Schlemmer, U.; Jany, K.D.; Berk, A.; Schulz, E.; Rechkemmer, G. Degradation of phytate in the gut of pigs—Pathway of gastro-intestinal inositol phosphate hydrolysis and enzymes involved. Arch. Anim. Nutr. 2001, 55, 255–280.
77. Sandberg, A.S.; Andersson, H. Effect of dietary phytases on the digestion of phytate in the stomach and small intestine of humans. J. Nutr. 1988, 118, 469–473. [CrossRef]
78. Kaewsorn, K.; Sirisomboon, P. Determination of the gamma-aminobutyric acid content of germinated brown rice by near infrared spectroscopy. J. Near Infrared Spectrosc. 2014, 22, 45–54. [CrossRef]
79. Shelp, B.J.; Bown, A.W.; McLean, M.D. Metabolism and functions of gamma-aminobutyric acid. Trends Plant Sci. 1999, 4, 446–452. [CrossRef]
80. Zhang, H.; Yao, H.Y.; Chen, F. Accumulation of γ-aminobutyric acid in rice germ using protease. Biosci. Biotechnol. Biochem. 2006, 70, 1160–1165. [CrossRef]
81. Dat, L.Q.; An, N.T.; Phung, L.T.K.; Nu, N.T.X. Gamma-amino butyric acid (GABA) synthesis of Lactobacillus in fermentation of defatted rice bran extract. In AIP Conference Proceedings; AIP Publishing LLC: New York, NY, USA, 2017; Volume 1878, p. 020045.
82. Dat, L.Q.; Ngan, T.T.K.; Nu, N.T.X. Gamma-amino butyric acid (GABA) production from rice bran. J. Agric. Food Chem. 2007, 54, 3130–3140. [CrossRef] [PubMed]
83. Kim, H.Y.; Hwang, I.G.; Kim, T.M.; Woo, K.S.; Park, D.S.; Kim, J.H.; Kim, D.J.; Lee, J.; Lee, Y.R.; Jeong, H.S. Chemical and functional components in different parts of rough rice (Oryza sativa L.) before and after germination. Food Chem. 2012, 134, 288–293. [CrossRef]
84. Chung, S.I.; Jin, X.; Kang, M.Y. Enhancement of glucose and bone metabolism in ovariectomized rats fed with germinated pigmented rice with giant embryo (Oryza sativa L. cv. Keunnunjami). Food Nutr. Res. 2019, 63. [CrossRef]
85. Hagiwara, H.; Seki, T.; Ariga, T. The effect of pre-germinated brown rice intake on blood glucose and PAI-1 levels in streptozotocin-induced diabetic rats. Biosci. Biotechnol. Biochem. 2004, 68, 444–447. [CrossRef]
86. Reboul, E. Vitamin E Bioavailability: Mechanisms of Intestinal Absorption in the Spotlight. Antioxidants 2017, 6, 95. [CrossRef]
87. Niki, E.; Abe, K. Vitamin E: Structure, properties and functions. In Vitamin E: Chemistry and Nutritional Benefits; Royal Society of Chemistry: London, UK, 2019; Chapter 1; pp. 1–11.
88. Qureshi, A.; Mo, H.; Packer, L.; Peterson, D. Isolation and identification of novel tocotrienols from rice bran with hypocholesterolemic, antioxidant and antitumor properties. J. Agric. Food Chem. 2000, 48, 3130–3140. [CrossRef] [PubMed]
89. Thilakavathy, S.; Pandeeswari, N.K. The glycemic index—Science based diet. Int. J. Pharm. Med. Bio. Sc. 2012, 1, 259–265.
90. ISO 26642:2010. [CrossRef]
91. Dat, L.Q.; An, N.T.; Phung, L.T.K.; Dung, N.H.; Long, N.Q. Technical assessment of gamma-amino butyric acid (GABA) production from rice bran. J. Sci. Technol. 2019, 57, 137–143.
92. Dat, L.Q.; Nguen, T.T.K.; Nu, N.T.X. Gamma-amino butyric acid (GABA) synthesis of Lactobacillus in fermentation of defatted rice bran extract. In AIP Conference Proceedings; AIP Publishing LLC: New York, NY, USA, 2017; Volume 1878, p. 020045.
93. Kim, H.Y.; Hwang, I.G.; Kim, T.M.; Woo, K.S.; Park, D.S.; Kim, J.H.; Kim, D.J.; Lee, J.; Lee, Y.R.; Jeong, H.S. Chemical and functional components in different parts of rough rice (Oryza sativa L.) before and after germination. Food Chem. 2012, 134, 288–293. [CrossRef]
94. Shim, M.; Zhang, Z.; Yua, S.; Wang, K.; Gilbert, R.; Gao, Q. Pea starch (Pisum sativum, L.) with slow digestion property produced using b-amylase and transglucosidase. Food Chem. 2014, 164, 317–323. [CrossRef]
95. Ina, S.; Ninomiya, K.; Mogi, T.; Hase, A.; Ando, T.; Matsuksae, N.; Oghiara, J.; Akao, M.; Kumagai, H.; Kumagai, H. Rice (Oryza sativa japonica) Albumin Suppresses the Elevation of Blood Glucose and Plasma Insulin Levels after Oral Glucose Loading. J. Agric. Food Chem. 2016, 64, 4882–4890. [CrossRef] [PubMed]
96. Tan, S.-Y.; Siow, P.C.; Peh, E.; Henry, C.J. Influence of rice, pea and oat proteins in attenuating glycemic response of sugar-sweetened beverages. Eur. J. Nutr. 2017, 57, 2795–2803. [CrossRef]
97. Diloroth, L.; Omoruyi, F.; Simon, O.; Morrison, E.S.A.; Asemota, H. The effect of phytic acid on the levels of blood glucose and some enzymes of carbohydrate and lipid metabolism. West Indian Med. J. 2005, 54, 102–106. [CrossRef] [PubMed]
98. Kuppusamy, A.; Muthusamy, U.; Andichetiar, T.S.; Varadharajan, S.; Ramasamy, K.; Ramanathan, S. In vitro (α-Glucosidase and α-Amylase Inhibition) and in vivo Antidiabetic Property of Phyric Acid (IP6) in Streptozotocin-Nicotinamide-Induced Type 2 Diabetes Mellitus (NIDDM) in Rats. J. Complementary Integr. Med. 2011, 8, 1–19. [CrossRef] [PubMed]
99. Kim, S.M.; Rico, C.W.; Lee, S.C.; Kang, M.Y. Modulatory Effect of Rice Bran and Phyric Acid on Glucose Metabolism in High Fat-Fed C57BL/6N Mice. J. Clin. Biochem. Nutr. 2010, 47, 12–17. [CrossRef] [PubMed]
100. Lee, S.-H.; Park, H.-J.; Chun, H.-K.; Cho, S.-Y.; Cho, S.-M.; Lillehoj, H.S. Dietary phyric acid lowers the blood glucose level in diabetic KK mice. Nutr. Res. 2006, 26, 474–479. [CrossRef]
99. Jung, E.H.; Kim, S.R.; Hwang, I.K.; Ha, T.Y. Hypoglycemic effects of a phenolic acid fraction of rice bran and ferulic acid in C57BL/KsJ-db/db mice. *J. Agric. FoodChem.* 2007, 55, 9800–9804. [CrossRef] [PubMed]

100. Tahrani, A.A.; Barnett, A.H.; Bailey, C.J. SGLT inhibitors in management of diabetes. *Curr. Opin. Nephrol. Hypertens.* 2015, 24, 463–469. [CrossRef] [PubMed]

101. Hussain, T. The role of intestinal sweet taste receptors (STRS) in the regulation of glucose absorption: Effects of short term high sucrose diet (HSD). In *HIM 1990-2015*; University of Central Florida: Orlando, FL, USA, 2014; Volume 1839, pp. 1–51.

102. Poulsen, S.B.; Fenton, R.A.; Riegel, T. Sodium-glucose cotransport. *Diabetes* 2004, 53, 1–17. [CrossRef] [PubMed]

103. Scheen, A.J. Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus. *Drugs* 2003, 63, 933–951. [CrossRef]

104. Kellett, G.L.; Brot-Laroco, E. Apical GLUT2: A Major Pathway of Intestinal Sugar Absorption. *Diabetes* 2005, 54, 3056–3062. [CrossRef] [PubMed]

105. Whitcomb, D.C.; Lowe, M.E. Human pancreatic digestive enzymes. *Dig. Dis. Sci.* 2007, 52, 1–17. [CrossRef] [PubMed]

106. Sobhy, R.; Eid, M.; Zhan, F.; Liang, H.; Li, B. Toward understanding the in vitro anti-amylolytic effects of three structurally different pectin/y amelobalins in an aqueous medium using multispectral and molecular docking studies. *J. Mol. Liq.* 2019, 283, 223–234. [CrossRef]

107. Untereiner, A.; Abdo, S.; Bhattacharjee, A; Kohler, H.; Pourasgari, F.; Chutong, N.; Batchuluun, B.; Wong, A.; Khuu, N.; et al. Protective and regenerative effects on islet beta cells and reverses diabetes. *Proc. Natl. Acad. Sci. USA* 2011, 108, 11692–11697. [CrossRef] [PubMed]

108. Han, S.-M.; Lee, J.-S. Production and Its Anti-hyperglycemic Effects of γ-Aminobutyric Acid from the Wild Yeast Strain Pichia silvicola UL6-1 and Sporobolomyces carnich 402-JB-1. *Myobiology* 2017, 45, 199–203. [CrossRef]

109. Wright, E.M.; Martín, M.G.; Turk, E. Intestinal absorption in health and disease—Sugar. *Best Pr. Res Clin Gastroenterol.* 2003, 17, 943–956. [CrossRef]

110. Hussain, T. The role of intestinal sweet taste receptors (STRS) in the regulation of glucose absorption: Effects of short term high sucrose diet (HSD). In *HIM 1990-2015*; University of Central Florida: Orlando, FL, USA, 2014; Volume 1839, pp. 1–51.

111. Poulsen, S.B.; Fenton, R.A.; Riegel, T. Sodium-glucose cotransport. *Curr. Opin. Nephrol. Hypertens.* 2015, 24, 463–469. [CrossRef] [PubMed]

112. Tahrani, A.A.; Barnett, A.H.; Bailey, C.J. SGLT inhibitors in management of diabetes. *Lancet Diabetes Endocrinol.* 2013, 1, 140–151. [CrossRef]

113. Ina, S.; Hamada, A.; Nakamura, H.; Yamaguchi, Y.; Kamagai, K.; Kamagai, H. Rice (*Oryza sativa japonica*) albumin hydrolysates suppress postprandial blood glucose elevation by adsorbing glucose and inhibiting Na+-d-glucose cotransporter SGLT1 expression. *J. Funct. Foods* 2020, 64, 103603. [CrossRef]

114. Woyengo, T.A.; Rodriguez-Lecompte, J.C.; Adeola, O.; Nyachoti, C.M. Histomorphology and small intestinal sodium-dependent glucose transporter 1 gene expression in piglets fed phytic acid- and phytase-supplemented diets. *J. Nutr. Metab.* 2016, 2016, 4981524. [CrossRef] [PubMed]

115. Malunga, L.N.; Eck, P.; Beta, T. Inhibition of Intestinal α-Glucosidase and Glucose Absorption by Feruloylated Arabinoxylan Mono- and Oligosaccharides from Corn Bran and Wheat Aleurone. *J. Nutr. Metab.* 2016, 1932532, 1–9. [CrossRef]

116. Soltani, N.; Qiu, H.; Alekic, M.; Glinka, Y.; Zhao, F.; Liu, R.; Li, Y.; Zhang, N.; Chakrabarti, R.; Ng, T.; et al. GABA exerts protective and regenerative effects on islet beta cells and reverses diabetes. *Proc. Natl. Acad. Sci. USA* 2011, 108, 11692–11697. [CrossRef] [PubMed]

117. Untereiner, A.; Abdo, S.; Bhattacharjee, A; Kohler, H.; Pourasgari, F.; Iheb, N.; Lai, M.; Batchuluun, B.; Wong, A.; Khuu, N.; et al. GABA promotes β-cell proliferation, but does not overcome impaired glucose homeostasis associated with diet-induced obesity. *FASEB J.* 2019, 33, 3968–3984. [CrossRef] [PubMed]

118. Kozu, C.; Sunagawa, S.; Ueda, R.; Higa, M.; Tanaka, H.; Shimizu-Okaie, C.; Takayama, S.I.C.; Matsushita, M.; Tsutsui, M.; Miyazaki, J.; et al. Y-Oryzanol Protects Pancreatic β-Cells Against Endoplasmic Reticulum Stress in Male Mice. *Endocrinology* 2015, 156, 1242–1250. [CrossRef] [PubMed]

119. Mukherjee, A.; Morales-Scheihing, D.; Salvadores, N.; Moreno-Gonzalez, I.; Gonzalez, C.; Taylor-Presse, K.; Mendez, N.; Shahnavaz, M.; Gaber, A.O.; Sabek, O.M.; et al. Inhibition of IAPP amyloid deposition and associated diabetic abnormalities by a prion-like mechanism. *J. Exp. Med.* 2017, 214, 2591–2610. [CrossRef] [PubMed]

120. Akter, R.; Cao, P.; Nook, H.; Ridgway, Z.; Tu, L.-H.; Wang, H.; Wong, A.G.; Zhang, X.; Abedini, A.; Schmidt, A.M.; et al. Islet amyloid polypeptide: Structure, function, and pathophysiology. *J. Diabetes Res.* 2016, 33, 1–18. [CrossRef]

121. Reddy, N.; Brender, J.R.; Vivekanandana, S.; Ramamoorthy, A. Structure and membrane orientation of IAPP in its natively amidated form at pH in a membrane environment. *Biochim. Biophys. Acta.* 2011, 1808, 2337–2342.

122. Kanatsuka, A.; Koy, S.; Makino, H. IAPP/amylin and betacell failure: Implication of the risk factors of type 2 diabetes. *Diabetol. Int.* 2018, 9, 143–157. [CrossRef]

123. Zhang, X.-X.; Pan, Y.-H.; Huang, Y.-M.; Zhao, H.-L. Neuroendocrine hormone amylin in diabetes. *World J. Diabetes* 2016, 7, 189–197. [CrossRef]

124. Clark, A.; Nilsson, M.R. Islet amyloid: A complication of islet dysfunction or an aetiologic factor in type 2 diabetes? *Diabetologia* 2004, 47, 157–169. [CrossRef]
125. Asthana, S.; Mallick, B.; Alexandrescu, A.T.; Jha, S. IAPP in type II diabetes: Basic research on structure, molecular interactions, and disease mechanisms suggests potential intervention strategies. *BBA Biomembr.* 2018, 1860, 1765–1782. [CrossRef] [PubMed]

126. Rungratanawanich, W.; Abate, G.; Uberti, D. Pharmacological profile of γ-oryzanol: Its antioxidant mechanisms and its effects in age-related diseases. In *Aging*; Academic Press: Cambridge, MA, USA, 2020; pp. 201–208.

127. Minatel, I.O.; Francisqueti, F.V.; Corrêa, C.R.; Lima, G.F.P. Antioxidant Activity of γ-Oryzanol: A Complex Network of Interactions. *Int. J. Mol. Sci.* 2016, 17, 1107. [CrossRef] [PubMed]

128. Huang, D.; Ou, B.; Hampsch-Woodill, M.; Flanagan, J.; Deemer, E. Development and validation of oxygen radical absorbance capacity assay for lipophilic antioxidants using randomly methylated β-cyclodextrin as the solubility enhancer. *J. Agric. Food Chem.* 2002, 50, 1815–1821. [CrossRef] [PubMed]

129. Huang, C.-C.J. Potential functionality and digestibility of oryzanol as determined using in vitro cell culture models. Ph.D. Dissertation, Louisiana State University and Agricultural and Mechanical College, Baton Rouge, LA, USA, 2003; pp. 1–159.

130. Chotimarkorn, C.; Ushio, H. The effect of trans-ferulic acid and gamma-oryzanol on ethanol-induced liver injury in C57BL mouse. *Phytomedicine* 2008, 15, 951–958. [CrossRef] [PubMed]

131. Ismail, M.; Al-Naqeeb, A.; Mamat, W.A.A.; Ahmad, Z. Gamma-oryzanol rich fraction regulates the expression of antioxidant and oxidative stress related genes in stressed rat’s liver. *Nutr. Metab.* 2010, 7, 1–13. [CrossRef]

132. Jin Son, M.W.; Rico, C.; Hyun Nam, S.; Young Kang, M. Influence of Oryzanol and Ferulic Acid on the Lipid Metabolism and Antioxidative Status in High Fat-Fed Mice. *J. Clin. Biochem. Nutr.* 2010, 46, 150–156. [CrossRef]

133. Spiazzii, C.C.; Manfredini, V.; Silva, F.E.; Flores, E.M.M.; Izaguirry, A.P.; Soares, M.B.; Santos, F.W. γ-Oryzanol protects against acute cadmium-induced oxidative damage in mice testes. *Food Chem. Toxicol.* 2013, 53, 526–532. [CrossRef]

134. Mirhashemi, S.M. To evaluate likely antiamyloidogenic property of ferulic acid and baicalein against human islet amyloid polypeptide aggregation, in vitro study. *Afr. J. Pharm. Pharmacol.* 2012, 6, 671–676. [CrossRef]

135. Kumar, V.; Sinha, A.K.; Makkar, H.P.S.; Becker, K. Dietary roles of phytate and phytase in human nutrition: A review. *J. Agric. Food Chem.* 2010, 120, 945–959. [CrossRef] [PubMed]

136. Nissar, J.; Ahad, T.; Naik, H.R.; Hussain, S.Z. A review phytic acid: As antinutrient or nutraceutical. *Phytother. Res.* 2017, 6, 1554–1560.

137. Omoruyi, F.O.; Budiaman, A.; Eng, Y.; Olumese, F.E.; Hoesel, J.L.; Ejilemele, A.; Okorodudu, A.O. The Potential Benefits and Adverse Effects of Phytic Acid Supplement in Streptozotocin-Induced Diabetic Rats. *Adv. Pharmacol. Sci.* 2013, 1, 1–7. [CrossRef] [PubMed]

138. Sanchis, P.; Rivera, R.; Berga, F.; Fortuny, R.; Adrover, M.; Costa-Bauza, A.; Grases, F.; Masmiquel, L. Phytate Decreases Formation of Advanced Glycation End-Products in Patients with Type II Diabetes: Randomized Crossover Trial. *Sci. Rep.* 2018, 8, 1–13. [CrossRef] [PubMed]

139. Srinivasan, M.; Sdheer, A.R.; Menon, V.P. Ferulic Acid: Therapeutic potential through its antioxidant property. *J. Clin. Biochem. Nutr.* 2007, 40, 92–100. [CrossRef] [PubMed]

140. Gohil, K.J.; Kshirsagar, S.B.; Sahane, R.S. Ferulic acid—A comprehensive 445 pharmacology of an important bioflavonoid. *Int. J. Pharm.* 2012, 7, 300–710. [CrossRef] [PubMed]

141. Prabhakar, P.K.; Prasad, R.; Ali, S.; Doble, M. Synergistic interaction of ferulic acid with commercial hypoglycemic drugs in streptozotocin induced diabetic rats. *Phytochemistry* 2013, 20, 488–494. [CrossRef]

142. Nomura, E.; Kashiwada, A.; Hosoda, A.; Nakamura, K.; Morishita, H.; Tsuchikura, S.; Takaiwa, F. Seed-specific expression of truncated OsGAD2 produces GABA-enriched rice grains that influence a decrease in blood pressure in spontaneously hypertensive rats. *J. Agric. Food Chem.* 2002, 18, 1860–1866. [CrossRef] [PubMed]

143. Jain, A.B.; Jain, V.A. Vitamin E, Its Beneficial Role in Diabetes Mellitus (DM) and Its Complications. *Adv. Pharmacol. Sci.* 2018, 34, 1–6. [CrossRef] [PubMed]

144. Napolitano, T.; Avolio, F.; Vieira, A.; Ben-Othman, N.; Courtney, M.; Gjernes, E.; Hadzic, B.; Druelle, N.; Sanz, S.N.; Silvano, S.; et al. GABA signaling stimulates α-cell-mediated β-like cell neogenesis. *Commun. Integr. Biol.* 2017, 10, e1300215. [CrossRef]

145. Jain, A.B.; Jain, V.A. Vitamin E, Its Beneficial Role in Diabetes Mellitus (DM) and Its Complications. *J. Clin. Diagn. Res.* 2012, 6, 1624–1628. [CrossRef]

146. Kneckt, P.; Reunanen, A.; Marniemi, J.; Leino, A.; Aromaa, A. Low vitamin E status is a potential risk factor for insulin-dependent diabetes mellitus. *J. Intern. Med.* 1999, 245, 99–102. [CrossRef] [PubMed]

147. Pazdro, R.; Burgess, J.R. The role of vitamin E and oxidative stress in diabetes complications. *Mech. Ageing Dev.* 2010, 131, 276–286. [CrossRef] [PubMed]

148. Fang, F.; Kang, Z.; Wang, C. Vitamin E tocotrienols improve insulin sensitivity through activating peroxisome proliferator-activated receptors. *J. Nutr. Food Res.* 2010, 54, 345–352. [CrossRef] [PubMed]